FDA/EMEA To Hold Joint Pharmacogenomic Meetings
This article was originally published in The Pink Sheet Daily
FDA and the European Medicines Agency will offer voluntary genomic data submission sponsors the option of joint FDA/EMEA briefing meetings, the agencies said May 31
You may also be interested in...
After releasing a final guidance for industry data submissions, FDA continues to seek input on additional pharmacogenomic guidances. The agency will release a concept paper on co-development of drugs and diagnostics for the April 11-13 workshop.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.